United Therapeutics Corporation logo

United Therapeutics Corporation (UTHR)

Market Open
15 Dec, 16:01
NASDAQ (NGS) NASDAQ (NGS)
$
492. 98
-1.01
-0.21%
$
21.71B Market Cap
11.96 P/E Ratio
0% Div Yield
93,670 Volume
24.04 Eps
$ 493.99
Previous Close
Day Range
487.42 498.59
Year Range
266.98 498.59
Want to track UTHR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 72 days
United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?

United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?

United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
United Therapeutics (UTHR) Completes Enrolment in IPF Study

United Therapeutics (UTHR) Completes Enrolment in IPF Study

United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.

Zacks | 1 year ago
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Big Money Elevating United Therapeutics

Big Money Elevating United Therapeutics

The medical devices and novel treatments United Therapeutics Corporation (UTHR) develops to treat pulmonary arterial hypertension (PAH) and other ailments are attracting substantial Big Money investment.

Fxempire | 1 year ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report?

Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago